Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
11:25am, Wednesday, 03'rd Jun 2026
GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.
UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags
07:56am, Wednesday, 03'rd Jun 2026
UBS has described the UK equity market as an "incomplete plate rather than an empty one" in its latest monthly strategy note, concluding that disciplined stock selection rather than broad index exposu
Why Is Glaxo (GSK) Down 2.1% Since Last Earnings Report?
12:31pm, Friday, 29'th May 2026
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
10:30am, Friday, 29'th May 2026
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that...
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
09:39am, Friday, 29'th May 2026
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any v
Sonoro Gold upsizes private placement to C$15M amid investor demand
05:14am, Friday, 29'th May 2026
Sonoro Gold Corp (TSX-V:SGO, OTCQB:SMOFF, FRA:23SP) said on Friday that it has increased the size of its previously announced non-brokered private placement...
GSK Drug Shows 19%-20% Hepatitis B Cure Rate In Late-Stage Trials
05:22pm, Thursday, 28'th May 2026
GSK (GSK) may have just strengthened the investment case around one of its most important pipeline assets. Late-stage data showed bepirovirsen, its experimental
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
03:44pm, Thursday, 28'th May 2026
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials
04:56am, Thursday, 28'th May 2026
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
04:31am, Thursday, 28'th May 2026
GSK said its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative
Here's Why GSK (GSK) is a Strong Value Stock
10:41am, Friday, 22'nd May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?
11:26am, Thursday, 21'st May 2026
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
08:24am, Tuesday, 19'th May 2026
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
02:22pm, Monday, 18'th May 2026
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
